Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Identifieur interne : 002983 ( PubMed/Curation ); précédent : 002982; suivant : 002984Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
Auteurs : Terry Nolan [Australie] ; Miguel O'Ryan [Chili] ; James Wassil [États-Unis] ; Véronique Abitbol [France] ; Peter Dull [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Activité bactéricide du sang, Adolescent, Anticorps antibactériens (sang), Humains, Infections à méningocoques (), Infections à méningocoques (épidémiologie), Jeune adulte, Neisseria meningitidis sérogroupe B (immunologie), Santé mondiale, Vaccins antiméningococciques (administration et posologie), Vaccins antiméningococciques (effets indésirables), Vaccins antiméningococciques (immunologie).
- MESH :
- administration et posologie : Vaccins antiméningococciques.
- effets indésirables : Vaccins antiméningococciques.
- immunologie : Neisseria meningitidis sérogroupe B, Vaccins antiméningococciques.
- sang : Anticorps antibactériens.
- épidémiologie : Infections à méningocoques.
- Activité bactéricide du sang, Adolescent, Humains, Infections à méningocoques, Jeune adulte, Santé mondiale.
English descriptors
- KwdEn :
- Adolescent, Antibodies, Bacterial (blood), Blood Bactericidal Activity, Global Health, Humans, Meningococcal Infections (epidemiology), Meningococcal Infections (prevention & control), Meningococcal Vaccines (administration & dosage), Meningococcal Vaccines (adverse effects), Meningococcal Vaccines (immunology), Neisseria meningitidis, Serogroup B (immunology), Young Adult.
- MESH :
- chemical , administration & dosage : Meningococcal Vaccines.
- chemical , adverse effects : Meningococcal Vaccines.
- chemical , blood : Antibodies, Bacterial.
- epidemiology : Meningococcal Infections.
- chemical , immunology : Meningococcal Vaccines, Neisseria meningitidis, Serogroup B.
- prevention & control : Meningococcal Infections.
- Adolescent, Blood Bactericidal Activity, Global Health, Humans, Young Adult.
Abstract
Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.
DOI: 10.1016/j.vaccine.2015.06.011
PubMed: 26187261
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A53
Links to Exploration step
pubmed:26187261Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.</title><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name><affiliation wicri:level="1"><nlm:affiliation>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010</wicri:regionArea></affiliation></author><author><name sortKey="O Ryan, Miguel" sort="O Ryan, Miguel" uniqKey="O Ryan M" first="Miguel" last="O'Ryan">Miguel O'Ryan</name><affiliation wicri:level="1"><nlm:affiliation>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago</wicri:regionArea></affiliation></author><author><name sortKey="Wassil, James" sort="Wassil, James" uniqKey="Wassil J" first="James" last="Wassil">James Wassil</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jimwassil@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea></affiliation></author><author><name sortKey="Abitbol, Veronique" sort="Abitbol, Veronique" uniqKey="Abitbol V" first="Véronique" last="Abitbol">Véronique Abitbol</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes</wicri:regionArea></affiliation></author><author><name sortKey="Dull, Peter" sort="Dull, Peter" uniqKey="Dull P" first="Peter" last="Dull">Peter Dull</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26187261</idno><idno type="pmid">26187261</idno><idno type="doi">10.1016/j.vaccine.2015.06.011</idno><idno type="wicri:Area/PubMed/Corpus">002A53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A53</idno><idno type="wicri:Area/PubMed/Curation">002983</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002983</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.</title><author><name sortKey="Nolan, Terry" sort="Nolan, Terry" uniqKey="Nolan T" first="Terry" last="Nolan">Terry Nolan</name><affiliation wicri:level="1"><nlm:affiliation>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010</wicri:regionArea></affiliation></author><author><name sortKey="O Ryan, Miguel" sort="O Ryan, Miguel" uniqKey="O Ryan M" first="Miguel" last="O'Ryan">Miguel O'Ryan</name><affiliation wicri:level="1"><nlm:affiliation>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile.</nlm:affiliation><country xml:lang="fr">Chili</country><wicri:regionArea>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago</wicri:regionArea></affiliation></author><author><name sortKey="Wassil, James" sort="Wassil, James" uniqKey="Wassil J" first="James" last="Wassil">James Wassil</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jimwassil@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea></affiliation></author><author><name sortKey="Abitbol, Veronique" sort="Abitbol, Veronique" uniqKey="Abitbol V" first="Véronique" last="Abitbol">Véronique Abitbol</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes</wicri:regionArea></affiliation></author><author><name sortKey="Dull, Peter" sort="Dull, Peter" uniqKey="Dull P" first="Peter" last="Dull">Peter Dull</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139</wicri:regionArea></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antibodies, Bacterial (blood)</term><term>Blood Bactericidal Activity</term><term>Global Health</term><term>Humans</term><term>Meningococcal Infections (epidemiology)</term><term>Meningococcal Infections (prevention & control)</term><term>Meningococcal Vaccines (administration & dosage)</term><term>Meningococcal Vaccines (adverse effects)</term><term>Meningococcal Vaccines (immunology)</term><term>Neisseria meningitidis, Serogroup B (immunology)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activité bactéricide du sang</term><term>Adolescent</term><term>Anticorps antibactériens (sang)</term><term>Humains</term><term>Infections à méningocoques ()</term><term>Infections à méningocoques (épidémiologie)</term><term>Jeune adulte</term><term>Neisseria meningitidis sérogroupe B (immunologie)</term><term>Santé mondiale</term><term>Vaccins antiméningococciques (administration et posologie)</term><term>Vaccins antiméningococciques (effets indésirables)</term><term>Vaccins antiméningococciques (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Meningococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Meningococcal Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Bacterial</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Meningococcal Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Neisseria meningitidis sérogroupe B</term><term>Vaccins antiméningococciques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Meningococcal Vaccines</term><term>Neisseria meningitidis, Serogroup B</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Meningococcal Infections</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antibactériens</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à méningocoques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Blood Bactericidal Activity</term><term>Global Health</term><term>Humans</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activité bactéricide du sang</term><term>Adolescent</term><term>Humains</term><term>Infections à méningocoques</term><term>Jeune adulte</term><term>Santé mondiale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26187261</PMID><DateCreated><Year>2015</Year><Month>08</Month><Day>24</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>36</Issue><PubDate><Year>2015</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.</ArticleTitle><Pagination><MedlinePgn>4437-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.06.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)00777-X</ELocationID><Abstract><AbstractText>Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines for use against serogroup B (MenB) outbreak strains but the diversity of MenB strains has limited vaccine use outside targeted geographic regions. MenB continues to be a significant cause of outbreaks in adolescents and young adults, as recently demonstrated in university settings in the US (Princeton, New Jersey and Santa Barbara, California) and has the potential for hyperendemic disease levels such as currently experienced in Québec and the United Kingdom. In adolescents, increased endemic disease rates and outbreak potential are likely associated with social behaviors putting individuals at risk for carriage acquisition and may explain regional and temporal variations in epidemiology. A protein-based, multi-component MenB vaccine (4CMenB) is currently licensed for use in 37 countries including EU/EEA countries, Australia, Canada, Chile, Colombia, Uruguay, and the US. In this article we review the most recent clinical trial data with 4CMenB with a focus on adolescents and young adults. The vaccine appears to have an acceptable safety profile and is well-tolerated in adolescents and young adults while providing robust, persistent levels of bactericidal antibodies considered protective for each of the four antigenic components of the vaccine. With the recent availability of this vaccine, health care providers have the first comprehensive opportunity to control meningococcal disease, a highly disruptive public health problem with a disproportionate impact on adolescents and young adults.</AbstractText><CopyrightInformation>Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, The University of Melbourne, and Murdoch Children's Research Institute, Victoria 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Ryan</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Programa de Microbiología y Micología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Avda Independencia 1027, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassil</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: jimwassil@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abitbol</LastName><ForeName>Véronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Novartis Vaccines and Diagnostics, Inc., S.A.S.10, Rue Chevreul, F-92150 Suresnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dull</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Novartis Vaccines and Diagnostics Inc., 350 Massachusetts Avenue, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C570015">4CMenB vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022401">Meningococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001770" MajorTopicYN="N">Blood Bactericidal Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008589" MajorTopicYN="N">Meningococcal Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022401" MajorTopicYN="N">Meningococcal Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038541" MajorTopicYN="N">Neisseria meningitidis, Serogroup B</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescents</Keyword><Keyword MajorTopicYN="N">Meningitis</Keyword><Keyword MajorTopicYN="N">Meningococcal B vaccine</Keyword><Keyword MajorTopicYN="N">Outbreak</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">University</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26187261</ArticleId><ArticleId IdType="pii">S0264-410X(15)00777-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.06.011</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002983 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002983 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26187261
|texte= Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26187261" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |